CareDx (CDNA) reported $86.68 million in revenue for the quarter ended June 2025, representing a year-over-year decline of 6.1%. EPS of $0.10 for the same period compares to $0.25 a year ago.
The reported revenue represents a surprise of -4.45% over the Zacks Consensus Estimate of $90.72 million. With the consensus EPS estimate being $0.12, the EPS surprise was -16.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how CareDx performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Patient and digital solutions: $12.81 million compared to the $11.91 million average estimate based on two analysts. The reported number represents a change of +19.2% year over year.
- Revenue- Testing services: $62.03 million compared to the $67.39 million average estimate based on two analysts. The reported number represents a change of -12.5% year over year.
- Revenue- Product: $11.83 million versus the two-analyst average estimate of $11.69 million. The reported number represents a year-over-year change of +11.5%.
View all Key Company Metrics for CareDx here>>>
Shares of CareDx have returned -33.3% over the past month versus the Zacks S&P 500 composite's +0.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CareDx, Inc. (CDNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
